Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


rebecca.brehm@oncology.ox.ac.uk


ORCID ID Rebecca Brehm

Rebecca Brehm

MSc Clinical Trials, BSc (Hons) Biological Sciences

Clinical Trial Administrator - Oncology Clinical Trials Office (OCTO)

I joined OCTO in June 2024 after completing my MSc studies in Clinical Trials at the Institute of Clinical Trials and Methodology at University College London (UCL). Prior to this, I worked as an Administrator for the Covid-19 Vaccination Programme at The Royal United Hospitals Bath NHS Foundation Trust.  

My research experience includes completing two systematic review research projects: (1) Exploring the use of point-of-care haemoglobin tests to diagnose childhood anaemia in low-and middle-income countries: A systematic review of clinical trials and observational studies (2) Investigating the effect of melatonin on metabolic control in type 2 diabetes and metabolic syndrome: A systematic review and meta-analysis of randomised controlled trials. 

Since joining OCTO, I have worked on the TebeMRD trial and assisted with close-out and archiving activities for several OCTO trials, including SCALOP-2, OCTOVA and IMAGO.

I am currently working on the LungVax trial.

LungVax: A Modular Cohort-Based Precision-Prevention Trial of neoantigen-targeting vaccines to prevent cancer in individuals at risk of recurrent or non-small cell lung cancer (NSCLC) and other cancers.